November 4, 2021
- Background: MSCs are adult stem cells found in several places in the body, including bone marrow, skin, and fat tissue. They are under investigation in MS because laboratory studies have suggested they can reduce immune activity, protect the nervous system from damage, and promote a tissue environment favorable to natural myelin repair processes.
- The “MESEMS” (MEsenchymal StEm cells for Multiple Sclerosis) trial involved 144 people up to 50 years of age with active (suggestive of ongoing inflammation) relapsing or active progressive MS. They infused participants’ own MSCs derived from their bone marrow and monitored results after 24 weeks. As a control, those randomly assigned to begin on placebo were later switched to MSCs, and those originally given MSCs were switched to placebo.
- After all participants had received MSCs, the total number of active (gadolinium-enhancing) lesions accumulated over 24 weeks was compared between the placebo period and the treatment period. There was no statistically significant difference between groups by this measure. MSC treatment was found to be safe and well tolerated.
- Note: This trial was not designed to assess the activity of MSC treatment on tissue repair or on slowing of disability. There are ongoing clinical trials of MSCs in MS, including ones focusing on augmenting nervous system repair, and ones that manipulate the cells to become more specialized stem cells that secrete many different potentially beneficial nervous system growth factors. Read more about ongoing research in mesenchymal stem cells for MS
- The study was funded by many health and MS-focused agencies in Canada and Europe.
Click to Subscribe for the MS Beacon eNewsletter and MS educational events
By: Stuart http://www.blogger.com/profile/[email protected]
Title: Results of International Mesenchymal Stem Cell Trial Suggest No Benefits Against Inflammation in Active MS
Sourced From: wwwmsviewsandrelatednews.blogspot.com/feeds/2826463793416628105/comments/default
Published Date: Tue, 30 Nov 2021 18:21:00 +0000